Dabigatran versus warfarin in patients with atrial fibrillation [3]

New England Journal of Medicine

Volumn 361, Issue 27, 2009, Pages 2672-

  Moia, Marco ^a   Mannucci, Pier Mannuccio ^a  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; DABIGATRAN; IDRAPARINUX; WARFARIN; XIMELAGATRAN; ANTICOAGULANT AGENT; BENZIMIDAZOLE DERIVATIVE; DABIGATRAN ETEXILATE; PYRIDINE DERIVATIVE;

BLEEDING; HEART ATRIUM FIBRILLATION; HEART VALVE; HUMAN; LETTER; MONOTHERAPY; PRIORITY JOURNAL; RISK ASSESSMENT; CHEMICALLY INDUCED DISORDER; DRUG COMBINATION; INCIDENCE; NOTE;

ANTICOAGULANTS; ASPIRIN; ATRIAL FIBRILLATION; BENZIMIDAZOLES; DRUG THERAPY, COMBINATION; HEMORRHAGE; HUMANS; INCIDENCE; PYRIDINES; WARFARIN;

EID: 74949113309     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: None     Document Type: Letter

References (4)

1. Connolly SJ, Pogue J, Eikelboom J, et al. Benefit of oral anti-coagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 2008;118:202937.
2. Olsson SB. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with nonvalvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 2003;362:16918.
3. Amadeus Investigators, Bousser MG, Bouthier J, et al. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, openlabel, noninferiority trial. Lancet 2008;371:31521.
4. Turpie AG, Gent M, Laupacis A, et al. A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement. N Engl J Med 1993;329:5249.